Results from the Global SYMPLICITY Registry presented at ACC 2014

Michael Böhm, co-chairman of the Global SYMPLICITY Registry, presented today during the late-breaking clinical trial session at the 63rd Scientific Sessions of the ACC the six month analysis of the first 1,000 patients enrolled in the open-label real-world patient registry.

Results from the Global SYMPLICITY Registry presented at ACC 2014

Michael Böhm (University of Saarland, Homburg/Saar, Germany) co-chairman of the Global SYMPLICITY Registry presented today during the late-breaking clinical trial session at the 63rd Scientific Sessions of the American College of Cardiology (ACC) the six month analysis of the first 1,000 patients enrolled in the open-label real-world patient registry. The Global SYMPLICITY Registry continues to demonstrate the safety of renal denervation with the Symplicity™ renal denervation system.

The results of the Symplicity HTN-3 are finally out!

Simultaneously to the presentation of Deepak L. Bhatt in the Late-Breaking Clinical Trials session, ACC meeting 2014 in Washington D.C., the results are now published online in The New England Journal of Medicine.

The results of the Symplicity HTN-3 are finally out!

Simultaneously to the presentation of Deepak L. Bhatt (Brigham and Women's Hospital, Boston, MA) in the Late-Breaking Clinical Trials session, 63rd Scientific Sessions of the American College of Cardiology (ACC) 2014 in Washington D.C., the results are now published online in The New England Journal of Medicine. 

An interview with Ajay Kirtane

Ajay Kirtane (United States) answers the following questions:

- Can you tell us more about the treatment of difficult to control hypertension in the US and about the prevalence?...

An interview with Riaz Dawood

Riaz Dawood (South Africa) answers the following questions: - Please tell us about the prevalence of hypertension and especially resistant hypertension in South Africa...

How to personalise combination therapy

RHC 2014 - Discover the presentations from the third session.

Download the slides if you would like to learn more about “personalised medicine” and the different possible antihypertensive drug combinations for the three “fil rouge” patients with elevated blood pressure: an elderly atherosclerotic patient, a metabolic patient and a young adrenergic patient.

Pages